Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.37 |
| ▸ | VDR | P11473 | 2/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 3/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30101401 | 0.91 | HCRTR1 (0.38) | CYSLTR1NR1H4VDRMRGPRX4BACE1 | |
| SCHEMBL21521010 | 0.90 | CYSLTR1 (0.40) | CYSLTR1NR1H4VDRMRGPRX4KDM4E | |
| SCHEMBL7862914 | 0.86 | ABCB1 (0.41) | ABCB1 | |
| SCHEMBL3948290 | 0.86 | ABCB1 (0.41) | ABCB1 | |
| SCHEMBL3955172 | 0.83 | HDAC8 (0.38) | BACE1ABCB1SLC2A1 | |
| SCHEMBL21521769 | 0.81 | HCRTR1 (0.40) | CYSLTR1NR1H4VDRMRGPRX4KDM4E | |
| SCHEMBL12519787 | 0.78 | NR1H2 (0.33) | ABCB1 | |
| SCHEMBL29039401 | 0.78 | CHRNB4 (0.47) | — | |
| SCHEMBL29410752 | 0.78 | CHRNB4 (0.47) | — | |
| SCHEMBL26999489 | 0.78 | CHRNB4 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| EP-4234551-A2 | PYRIDAZINONES AS PARP7 INHIBITORS | Ribon Therapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2023-06-22 | — | — | US | disclosed |
| EP-3788040-B1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS INC (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11566020-B1 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | CYSLTR1 4202/4885NR1H4 4127/4885VDR 1079/4885 |
| US-11566020-B1 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | CYSLTR1 4202/4885NR1H4 4127/4885VDR 1079/4885 |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | CYSLTR1 4202/4885NR1H4 4127/4885VDR 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.